NCT01636570

Vitamin D3 Supplementation for Heart Failure Patients

Double-Blind, Placebo-Controlled Trial of Vitamin D3 (Cholecalciferol) Supplementation for Heart Failure Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Heidi Moretti, MS, RD · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if treatment with vitamin D3 of 10,000 International Units (IU) daily in vitamin D deficient patients for 6 months will improve B type natriuretic peptide (BNP), a marker of heart function, compared to placebo. The investigators also aim to determine if vitamin D helps cardiopulmonary function as evaluated by cardiopulmonary exercise test (CPX), laboratory values, strength, and quality of life in patients with stable congestive heart failure (Class II or III).

Conditions

• Heart Failure
• Vitamin D Deficiency
• Cardiomyopathy
• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Placebo Comparator: Sugar Pill	Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
DRUG	Vitamin D3 (cholecalciferol)	10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.

Timeline

• Start date: 2012-08-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2012-07-10
• Last updated: 2017-04-26

Locations

2 sites across 1 country: United States